Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merrion, Novo Nordisk To Collaborate On Oral Insulin Analogues

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite giving up on inhaled insulin earlier this year, deal continues Novo Nordisk’s focus on enhancements to insulin formulation and delivery.

You may also be interested in...



Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets

Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.

Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets

Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.

Don’t Forget Injectable Insulin, Novo Nordisk Says

In the rush to develop new diabetes drugs, big pharma's focus has been mainly on anti-diabetic agents that prolong a patient's transition to insulin or on developing easier routes of administration for insulin that do away with the need for pesky needles

Related Content

Topics

UsernamePublicRestriction

Register

PS067061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel